Lynx1 capital buys Cullinan Therapeutics (CGEM) shares worth $9.8m

Lynx1 Capital Management LP, along with Weston Nichols, reported purchasing shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a $437.74 million market cap biotech company, in three separate transactions, with a total value of $9,826,941. The timing appears strategic, as InvestingPro data shows the stock has gained over 25% in the past week.

According to a Form 4 filing with the Securities and Exchange Commission, the purchases occurred between October 8 and October 10, 2025. The shares were bought at prices ranging from $6.46 to $7.3617.

Specifically, on October 8, 556,300 shares were purchased; on October 9, 626,043 shares were purchased; and on October 10, 277,298 shares were purchased. Following these transactions, Lynx1 Capital Management LP and Weston Nichols now own 8,549,084 shares of Cullinan Therapeutics.

In other recent news, Cullinan Oncology has been the focus of several updates, particularly regarding its clinical trials and analyst ratings. H.C. Wainwright has reiterated its Buy rating on Cullinan Oncology, maintaining a price target of $24.00. This follows the presentation of updated data from the Phase 2b REZILIENT1 trial of zipalertinib, which was shared at the World Conference on Lung Cancer. The trial targets non-small cell lung cancer patients with specific mutations who have previously received amivantamab treatment.

Additionally, Cullinan Oncology, in partnership with Taiho Pharmaceutical, plans to present further efficacy and safety data from this trial at the upcoming World Conference on Lung Cancer in Barcelona. This anticipated presentation is seen as a key catalyst for the company. H.C. Wainwright has also highlighted Cullinan’s CLN-978, describing it as a potential first-in-class treatment for autoimmune diseases, emphasizing its differentiated safety profile. These developments reflect ongoing advancements in Cullinan’s therapeutic pipeline and continued interest from analysts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.